Healthcare Use and Costs of Medium-chain Acyl-Coa Dehydrogenase Deficiency in Australia: Screening Versus No Screening
- 31 August 2007
- journal article
- research article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 151 (2), 121-126.e1
- https://doi.org/10.1016/j.jpeds.2007.03.011
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort studyThe Lancet, 2007
- Economics of tandem mass spectrometry screening of neonatal inherited disordersInternational Journal of Technology Assessment in Health Care, 2006
- Comprehensive Cost-Utility Analysis of Newborn Screening StrategiesPEDIATRICS, 2006
- Newborn Screening by Tandem Mass Spectrometry for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: A Cost-Effectiveness AnalysisPEDIATRICS, 2003
- Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn ScreeningPEDIATRICS, 2002
- Newborn screening with tandem mass spectrometry: Examining its cost-effectiveness in the Wisconsin Newborn Screening PanelThe Journal of Pediatrics, 2002
- Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Mutations Identified by MS/MS-Based Prospective Screening of Newborns Differ from Those Observed in Patients with Clinical Symptoms: Identification and Characterization of a New, Prevalent Mutation That Results in Mild MCAD Deficiency*American Journal of Human Genetics, 2001